These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

927 related articles for article (PubMed ID: 33552089)

  • 1. Variable Expression of Programmed Cell Death Protein 1-Ligand 1 in Kidneys Independent of Immune Checkpoint Inhibition.
    Hakroush S; Kopp SB; Tampe D; Gersmann AK; Korsten P; Zeisberg M; Tampe B
    Front Immunol; 2020; 11():624547. PubMed ID: 33552089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Compartmentalization of Intrarenal Programmed Cell Death Protein 1-Ligand 1 and Its Receptor in Kidney Injury Related to Immune Checkpoint Inhibitor Nephrotoxicity.
    Tampe D; Kopp SB; Baier E; Hakroush S; Tampe B
    Front Med (Lausanne); 2022; 9():902256. PubMed ID: 35755033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune checkpoint inhibitors induce acute interstitial nephritis in mice with increased urinary MCP1 and PD-1 glomerular expression.
    Martinez Valenzuela L; Gómez-Preciado F; Guiteras J; Antón Pampols P; Gomà M; Fulladosa X; Cruzado JM; Torras J; Draibe J
    J Transl Med; 2024 May; 22(1):421. PubMed ID: 38702780
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Study protocol: a prospective single-center study for non-invasive biomonitoring of renal complications in cancer patients treated with immune checkpoint inhibitors.
    Baier E; Korsten P; Strauß A; Thoms KM; Overbeck T; Ströbel P; Tampe B
    Front Immunol; 2023; 14():1140677. PubMed ID: 37180131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute kidney injury associated with anti-PD-1 and anti-PD-L1 drugs: a meta-analysis of randomized clinical trials.
    Lima IG; Silva IBUCD; Pípolo VC; Delfino VDA; Bignardi PR
    Immunopharmacol Immunotoxicol; 2024 Aug; 46(4):470-481. PubMed ID: 38825890
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Use of Immune Checkpoint Inhibitors in Oncology and the Occurrence of AKI: Where Do We Stand?
    Franzin R; Netti GS; Spadaccino F; Porta C; Gesualdo L; Stallone G; Castellano G; Ranieri E
    Front Immunol; 2020; 11():574271. PubMed ID: 33162990
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential treatment responses to immune checkpoint inhibitor (ICI) therapy in a case of multiple primary malignancies: the programmed death ligand-1 (PD-L1) negative ureteral and lung metastasis from a clear cell renal cell carcinoma appearing after robotic-assisted partial nephrectomy progressed after ICI therapy, while synchronous PD-L1-positive primary lung squamous cell carcinoma responded very well to ICI therapy: a case report.
    Urushibara M; Ishizaka K; Matsutani N; Takahashi M; Nagata M; Okumura T; Matsumoto Y; Tatsuoka S; Nenohi T; Amemiya T; Shimizu Y; Shirakawa T; Kato D
    World J Surg Oncol; 2023 Feb; 21(1):37. PubMed ID: 36747242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum sodium levels associate with recovery of kidney function in immune checkpoint inhibitor nephrotoxicity.
    Tampe D; Baier E; Hakroush S; Tampe B
    Front Med (Lausanne); 2023; 10():1020691. PubMed ID: 37547603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mortality after acute kidney injury and acute interstitial nephritis in patients prescribed immune checkpoint inhibitor therapy.
    Baker ML; Yamamoto Y; Perazella MA; Dizman N; Shirali AC; Hafez N; Weinstein J; Simonov M; Testani JM; Kluger HM; Cantley LG; Parikh CR; Wilson FP; Moledina DG
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35354588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Predictive Value of Programmed Death Ligand 1 in Patients with Metastatic Renal Cell Carcinoma Treated with Immune-checkpoint Inhibitors: A Systematic Review and Meta-analysis.
    Mori K; Abufaraj M; Mostafaei H; Quhal F; Fajkovic H; Remzi M; Karakiewicz PI; Egawa S; Schmidinger M; Shariat SF; Gust KM
    Eur Urol; 2021 Jun; 79(6):783-792. PubMed ID: 33172722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Programmed cell death-1 (PD-1) and programmed death-ligand 1 (PD-L1) expression in PD-1 inhibitor-associated colitis and its mimics.
    Cassol CA; Owen D; Kendra K; Braga JR; Frankel WL; Arnold CA
    Histopathology; 2020 Aug; 77(2):240-249. PubMed ID: 32298485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence and Clinical Features of Immune-Related Acute Kidney Injury in Patients Receiving Programmed Cell Death Ligand-1 Inhibitors.
    Seethapathy H; Zhao S; Strohbehn IA; Lee M; Chute DF; Bates H; Molina GE; Zubiri L; Gupta S; Motwani S; Leaf DE; Sullivan RJ; Rahma O; Blumenthal KG; Villani AC; Reynolds KL; Sise ME
    Kidney Int Rep; 2020 Oct; 5(10):1700-1705. PubMed ID: 33102962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
    Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
    Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urinary soluble PD-1 as a biomarker of checkpoint inhibitor-induced acute tubulointerstitial nephritis.
    Gomez-Preciado F; Martinez-Valenzuela L; Anton-Pampols P; Fulladosa X; Tena MG; Gomà M; Jove M; Nadal E; Merino-Ribas A; Martin-Alemany N; Cruzado JM; Torras J; Draibe J
    Clin Kidney J; 2024 Aug; 17(8):sfae200. PubMed ID: 39131079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of tumor mutation burden, PD-L1 and DNA repair genes to assess relationship to immune checkpoint inhibitors response in metastatic renal cell carcinoma.
    Labriola MK; Zhu J; Gupta RT; McCall S; Jackson J; Kong EF; White JR; Cerqueira G; Gerding K; Simmons JK; George D; Zhang T
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32221016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Periodontitis is an immune-related adverse event associated with immune checkpoint inhibitors: A multi-center cohort study.
    Ma KS; Chiang CH; Chen ST; Dinh Y; Chiang CH; Van Dyke TE; Sullivan R; Ananthakrishnan AN; Hsia YP; Peng CM; Chiang CH
    Cancer Lett; 2024 Aug; 598():217100. PubMed ID: 38969158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Questionnaire-based detection of immune-related adverse events in cancer patients treated with PD-1/PD-L1 immune checkpoint inhibitors.
    Griewing LM; Schweizer C; Schubert P; Rutzner S; Eckstein M; Frey B; Haderlein M; Weissmann T; Semrau S; Gostian AO; Müller SK; Traxdorf M; Iro H; Zhou JG; Gaipl US; Fietkau R; Hecht M
    BMC Cancer; 2021 Mar; 21(1):314. PubMed ID: 33761922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Incidence and Risk of PD-1/PD-L1 Inhibitor-associated Pneumonia in Advance Cancer Patients: A Meta-analysis].
    Chen K; Sun B
    Zhongguo Fei Ai Za Zhi; 2020 Nov; 23(11):927-940. PubMed ID: 33203196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence, predictors and 6-month overall outcome of acute kidney injury in Chinese patients receiving PD-1 inhibitors.
    Qin Z; Liu K; Xu X; Li T; Ge Y; Wu B; Xing C; Mao H
    Future Oncol; 2022 May; 18(16):1951-1962. PubMed ID: 35232231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nephrotoxicity in the Age of Immune Checkpoint Inhibitors: Mechanisms, Diagnosis, and Management.
    Moturi K; Sharma H; Hashemi-Sadraei N
    Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 47.